
Opinion|Videos|October 25, 2024
Emerging Trends and Rising Prevalence of mCSPC
Key Takeaways
- Improved diagnostic techniques and an aging population contribute to the increasing prevalence of mCSPC.
- Earlier detection and personalized therapeutic strategies are becoming more common in mCSPC management.
Panelists discuss how the prevalence of metastatic castration-sensitive prostate cancer (mCSPC) has been increasing, potentially influenced by changes in prostate-specific antigen screening recommendations and rising diagnoses of metastatic hormone-sensitive prostate cancer.
Advertisement
Episodes in this series

Now Playing
Video content above is prompted by the following:
What is the prevalence of mCSPC? What trends have emerged in recent years?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
AI-generated profiles impersonate female urologists to market ED products online
2
John Sfakianos, MD, discusses evolving management of recurrent LG-IR-NMIBC
3
Doublet or triplet? Urologists weighs in on mCSPC options
4
Interpreting real-world evidence in ARPI treatment decisions, with Martin Schoen, MD, PhD
5






